Immune Checkpoint Inhibitors in Human Glioma Microenvironment.
Amina Ghouzlani,Sarah Kandoussi,Mariam Tall,Konala Priyanka Reddy,Soumaya Rafii,Abdallah Badou +5 more
TL;DR: In this article, a review of the general concept of immune response within the brain and glioma microenvironment is presented, and some promising therapeutic pathways, including immune checkpoint blockade and the body's effective anti-glioma immune response are discussed.
read more
Abstract: Gliomas are the most common primary brain tumors in adults. Despite the fact that they are relatively rare, they cause significant morbidity and mortality. High-grade gliomas or glioblastomas are rapidly progressing tumors with a very poor prognosis. The presence of an intrinsic immune system in the central nervous system is now more accepted. During the last decade, there has been no major progress in glioma therapy. The lack of effective treatment for gliomas can be explained by the strategies that cancer cells use to escape the immune system. This being said, immunotherapy, which involves blockade of immune checkpoint inhibitors, has improved patients' survival in different cancer types. This novel cancer therapy appears to be one of the most promising approaches. In the present study, we will start with a review of the general concept of immune response within the brain and glioma microenvironment. Then, we will try to decipher the role of various immune checkpoint inhibitors within the glioma microenvironment. Finally, we will discuss some promising therapeutic pathways, including immune checkpoint blockade and the body's effective anti-glioma immune response.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Immunotherapy in glioblastoma treatment: Current state and future prospects
Samuel Luca Rocha Pinheiro,Fabian Fellipe Bueno Lemos,Hanna Santos Marques,Marcel Silva Luz,Mariana Santos Calmon,Matheus Sande Loureiro,Fabrício Freire de Melo +6 more
TL;DR: In this paper , the authors provide an overview of the current status and progress in immunotherapy for glioblastoma, going through the fundamental knowledge on immune targeting to promising strategies, such as Chimeric antigen receptor T-Cell therapy, immune checkpoint inhibitors, cytokine-based treatment, oncolytic virus and vaccine-based techniques.
41
The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis
TL;DR: In this paper, the expression and role of VISTA, a newly described immune checkpoint regulator, in human gliomas, was investigated through RNA-seq data of 667 glioma patients.
35
Opportunities for improving brain cancer treatment outcomes through imaging-based mathematical modeling of the delivery of radiotherapy and immunotherapy.
David A. Hormuth,Maguy Abdellah Farhat,Chase Christenson,Brandon James Curl,C. Chad Quarles,Caroline Chung,Thomas E. Yankeelov +6 more
TL;DR: In this paper , the authors present approaches to personalize mechanism-based modeling frameworks with patient data, and then discuss how these techniques could be leveraged to improve brain cancer outcomes through patient-specific modeling and optimization of treatment strategies.
30
The immunosuppressive microenvironment and immunotherapy in human glioblastoma
Xuehua Zhang,Leilei Zhao,Hecui Zhang,Yurui Zhang,Huanyu Ju,Xiaoyu Wang,Huan Ren,Xiao Zhu,Yucui Dong +8 more
TL;DR: In this article , the key immunosuppressive components in the tumor microenvironment, along with the regulatory mechanism of the gut microbiota involved in immunity and metabolism in the GBM microenvironment are discussed.
CAR T-cells for colorectal cancer immunotherapy: Ready to go?
TL;DR: The use of CAR T-cells has revolutionized the therapeutic approach for hematological malignancies, but there is a long way to go before this treatment can be developed for solid tumors, including colorectal cancer as discussed by the authors .
References
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Andreas D. Hartkopf,Florin-Andrei Taran,Markus Wallwiener,Christina B. Walter,Bernhard K. Krämer,Eva-Maria Grischke,Sara Y. Brucker +6 more
TL;DR: This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N. Louis,Arie Perry,Guido Reifenberger,Andreas von Deimling,Dominique Figarella-Branger,Webster K. Cavenee,Hiroko Ohgaki,Otmar D. Wiestler,Paul Kleihues,David W. Ellison +9 more
TL;DR: The 2016 World Health Organization Classification of Tumors of the Central Nervous System is both a conceptual and practical advance over its 2007 predecessor and is hoped that it will facilitate clinical, experimental and epidemiological studies that will lead to improvements in the lives of patients with brain tumors.
The blockade of immune checkpoints in cancer immunotherapy
TL;DR: Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
Structural and functional features of central nervous system lymphatic vessels
Antoine Louveau,Igor Smirnov,Timothy J. Keyes,Jacob D. Eccles,Sherin J. Rouhani,J. David Peske,Noël C. Derecki,David Castle,James Mandell,Kevin S. Lee,Tajie H. Harris,Jonathan Kipnis +11 more
TL;DR: In searching for T-cell gateways into and out of the meninges, functional lymphatic vessels lining the dural sinuses are discovered, which may call for a reassessment of basic assumptions in neuroimmunology and sheds new light on the aetiology of neuroinflammatory and neurodegenerative diseases associated with immune system dysfunction.
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
TL;DR: A better understanding of the molecular basis of myelomonocytic cell plasticity will open new vistas in immunopathology and therapeutic intervention and provide a paradigm for macrophage plasticity and function.
3.6K